- Else Nutrition (BABY) has concluded a preclinical study on its plant-based, soy-free infant formula
- This study demonstrates the safety and nutrient bioavailability of the Else infant formula
- Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition sat down with Shoran Devi to discuss the news
- Else Nutrition is focused on developing innovative, clean and plant-based food and nutrition products
- Else Nutrition Holdings (BABY) is currently trading at C$1.16 per share
Else Nutrition (BABY) has concluded a preclinical study on its plant-based, soy-free infant formula, on the pathway to bring its formulation to market.
This successful trial marks the key first step on the path with the Food and Drug Administration (FDA), as well as with other regulatory authorities, to demonstrate the safety and nutrient bioavailability of the Else infant formula.
Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition sat down with Shoran Devi to discuss the news.
Else Nutrition is focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula.
Else Nutrition Holdings (BABY) is currently trading at C$1.16 per share.
